Search

Displaying results 4861 - 4870 of 6830 in total
  1. Drug

    DLO6002

    go.drugbank.com/drugs/DB05179
    Experimental

    DLO6002 is developed by Summit Corporation and is in phase I of clinical trials for the treatment of Parkinson's disease.

  2. Drug

    Orbifloxacin

    go.drugbank.com/drugs/DB11443
    ExperimentalVet approved

    It is marketed by Schering-Plough Animal Health and approved for certain infections in dogs.

  3. Drug

    Domofenogene zalfaparvovec

    go.drugbank.com/drugs/DB16810
    Investigational

    Domofenogene zalfaparvovec, formerly known as BMN-307, is an investigational AAV5-phenylalanine hydroxylase (PAH) gene therapy developed by BioMarin Pharmaceutical.

  4. Drug

    Trifluoroethanol

    go.drugbank.com/drugs/DB03226
    Experimental

    A non-aqueous co-solvent that serves as tool to study protein folding. It is also used in various pharmaceutical, chemical and engineering applications.

  5. Drug

    Inbakicept

    go.drugbank.com/drugs/DB16479
    Investigational

    [L50592] This combination product was approved by the FDA on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without … It is one of the active ingredients in Anktiva, a combination product also containing [nogapendekin alfa], where a single inbakicept is complexed with two nogapendekin alfa components.

  6. Drug

    Abemaciclib

    go.drugbank.com/drugs/DB12001
    ApprovedInvestigational

    Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA gr...

  7. Drug

    MIP-1095 I-123

    go.drugbank.com/drugs/DB12994
    Experimental

    123 I Mip 1095 is under investigation in clinical trial NCT00712829 (Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents)

  8. Drug

    PI-0824

    go.drugbank.com/drugs/DB05516
    Investigational

    The goal of this therapy is to reduce the production of antibodies that cause PV blisters by acting only on the disease causing components of the immune system. … People with PV produce antibodies that attack the cells of the skin, resulting in blisters which, if left untreated, can lead to devastating infections and discomfort.

  9. Drug

    MB-07803

    go.drugbank.com/drugs/DB05053
    Investigational

    It is designed to block the metabolic pathway in the liver that is responsible for producing glucose.

  10. Drug

    NCX 1015

    go.drugbank.com/drugs/DB05825
    Experimental

    NCX 1015 is nitric oxide-releasing derivative of prednisolone developed for the treatment of inflammatory bowel disease (IBD) by NicOx SA.